Issue: March / April 2025

Wuxi Tides – Accelerating Complex Oligonucleotide Therapies

13 May 2025 No Comments

The FDA approval of the first siRNA drug in 2018 marked a key milestone for RNAi therapeutics, confirming the potential of gene-silencing oligonucleotides (1). Small interfering RNAs (siRNAs) selectively silence disease-related genes, enabling targeted treatments for genetic and metabolic diseases.

Read More »

30 Years of Transforming the CDMO Industry – A Chemist’s Perspective

12 May 2025 No Comments

Being part of today’s Contract Development and Manufacturing Organization (CDMO) industry feels significantly different to two decades ago, when I began my professional career as a chemist. Back then, CDMOs were referred to as Contract Manufacturing Organizations (CMOs), and the concept of contract manufacturing as a business model was just starting to take shape…

Read More »
@2019 - All Right Reserved. Designed and Developed by PenciDesign

Login